•In early 2023, a private conference with pharmaceutical industry leaders and investors highlighted anti-obesity and Alzheimer’s drugs as the next big money-makers and had the FDA head as its keynote speaker.
•Since then, the FDA has taken questionable steps to promote these drugs, particularly Ozempic, an anti-obesity medication. There's been a massive push to get everyone, including children, on Ozempic, using shockingly aggressive marketing tactics.
•This rush is eerily similar to the fen-phen craze, a temporary weight loss drug later pulled from the market for causing severe heart and lung issues.
•Worse, Ozempic comes with serious side effects, including paralyzing the digestive tract. This article will address the above controversy and explore the common causes of obesity, including those rarely discussed.
Ozempic, "obesitatearen aurkako medikamentua" omen da.
Oso polemikoa, itzelezko burujatetza eta iruzurra, antza, horretan ere.
Izugarrikeria itzelak ikusita gauden mundu honetan, tamalez horrelakoak ere (inoren osasuna laguntzeko ordaintzen dugun mediku sistema bereko eragile handiak ustelkeria handi batean murgilduta edota eragile) arrunt egiten zaizkigu.
No comments:
Post a Comment